Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Poniard Pharmaceuticals
(OTCEM:PARD)
Intraday
$0.0001
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$0.0001
0
[0.00%]
At close: Mar 26
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Poniard Pharmaceuticals Stock (OTC:PARD)
Poniard Pharmaceuticals Stock (OTC: PARD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, January 03, 2012
UPDATE: Poniard Pharmaceuticals Common Stock to Be Delisted From Nasdaq Stock Market, Intention to List on OTC Bulletin Board
Benzinga
-
Jan 3, 2012, 8:12AM
Friday, December 30, 2011
Poniard Pharmaceuticals Delisting to Pink Sheets on Tuesday January 3, 2012
Benzinga
-
Dec 30, 2011, 1:15PM
Saturday, November 19, 2011
Microcap Movers For Friday November 18, 2011
Benzinga
-
Nov 19, 2011, 3:05PM
Friday, November 18, 2011
Poniard Pharmaceuticals Announces Licensing Agreement for Focal Adhesion Kinase Technology
Benzinga
-
Nov 18, 2011, 8:30AM
Wednesday, November 09, 2011
ISS Proxy Advisory Services Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split
Benzinga
-
Nov 9, 2011, 8:32AM
Monday, November 07, 2011
Glass Lewis Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split
Benzinga
-
Nov 7, 2011, 8:32AM
Friday, October 28, 2011
Egan-Jones Recommends Poniard Shareholders Vote "FOR" Poniard's Proposed Merger With ALLOZYNE and Reverse Stock Split
Benzinga
-
Oct 28, 2011, 8:33AM
Tuesday, September 06, 2011
Poniard Pharmaceuticals Receives Favorable NASDAQ Decision for Continued Listing of Company Shares
Benzinga
-
Sep 6, 2011, 8:42AM
Poniard Pharmaceuticals Receives Favorable NASDAQ Decision for Continued Listing of Company Shares
Benzinga
-
Sep 6, 2011, 8:41AM
Monday, July 25, 2011
Poniard May be Delisted by NASDAQ
Benzinga
-
Jul 25, 2011, 2:13PM
Monday, July 11, 2011
Poniard Pharmaceuticals Adjourns Reconvened Annual Meeting of Shareholders to Solicit Additional Proxies for Important Reverse Stock Split Proposal
Benzinga
-
Jul 11, 2011, 11:51AM
Tuesday, July 05, 2011
Poniard Pharmaceuticals Announces Intention to Adjourn Annual Meeting of Shareholders to Solicit Additional Proxies for Reverse Stock Split Proposal
Benzinga
-
Jul 5, 2011, 8:32AM
Wednesday, June 22, 2011
Poniard Pharmaceuticals Surges On Merger News With Allozyne
Benzinga
-
Jun 22, 2011, 5:05PM
UPDATE: Poniard Pharmaceuticals Resumes Trading; Up Over 35%
Benzinga
-
Jun 22, 2011, 4:59PM
UPDATE: Poniard Pharmaceuticals Resumes Trading at 4:55pm
Benzinga
-
Jun 22, 2011, 4:42PM
Poniard Pharmaceuticals and ALLOZYNE Sign Definitive Merger Agreement
Benzinga
-
Jun 22, 2011, 4:27PM
Poniard Pharmaceuticals Halted, Pending News
Benzinga
-
Jun 22, 2011, 4:22PM
Tuesday, May 31, 2011
Poniard Pharmaceuticals Board of Directors Urges Shareholders to Vote FOR Reverse Stock Split Proposal
Benzinga
-
May 31, 2011, 2:17PM
Poniard Says 2 Proxy Firms Recommend Vote For Reverse Stock Split -Bloomberg
Benzinga
-
May 31, 2011, 1:05PM
Wednesday, March 30, 2011
Poniard Pharma Beats EPS By $0.02 (PARD)
Benzinga
-
Mar 30, 2011, 4:43PM
Poniard Pharmaceuticals Reports Q4 EPS $(0.11)
Benzinga
-
Mar 30, 2011, 4:41PM
Thursday, January 20, 2011
PARD And MOBI Hitting Intra-Day Highs
Benzinga
-
Jan 20, 2011, 10:55AM
Tuesday, December 21, 2010
Small Biotechnology Hot, Is Labopharm Next?
Benzinga
-
Dec 21, 2010, 2:21PM
Thursday, December 16, 2010
Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan
Benzinga
-
Dec 16, 2010, 8:07AM
Wednesday, December 08, 2010
Biotechnology Stocks Hot Off Of Orexigen Panel Vote
Benzinga
-
Dec 8, 2010, 1:01PM
Tuesday, November 09, 2010
Poniard Pharmaceuticals Reports Third Quarter 2010 Financial Results: Loss Per Share of $0.13
Benzinga
-
Nov 9, 2010, 4:23PM
Sunday, March 21, 2010
How Will Obama-Care Play Into The Markets And ETFs?
Benzinga
-
Mar 21, 2010, 9:50PM
Monday, January 25, 2010
Feuerstein Sees PARD as Case of “Sell On News”
Benzinga
-
Jan 25, 2010, 9:47AM
Benzinga’s Top Downgrades (STP, STJ, GPC, PARD)
Benzinga
-
Jan 25, 2010, 9:30AM
Benzinga’s Top Pre-Market Losers (PARD, DLTR, GENZ, SNDA, ACOR, TTHI, HCBK)
Benzinga
-
Jan 25, 2010, 8:44AM
Friday, January 08, 2010
Top 5 Most Advanced NASDAQ Stocks (ZUMZ, INSP, SHLD, HRTN, PARD)
Benzinga
-
Jan 8, 2010, 10:24AM
Thursday, December 03, 2009
Interesting Trade in Poniard
Benzinga
-
Dec 3, 2009, 12:09PM
Wednesday, November 18, 2009
Benzinga’s Top Pre- Market Gainers (VVUS, PARD, CSUN, SOLF, NLST, ASMI, CAKE)
Benzinga
-
Nov 18, 2009, 9:08AM
Monday, November 16, 2009
Biggest Losers (CAEI, TBV, PARD, CRXX, HOOK, ADY)
Benzinga
-
Nov 16, 2009, 10:50AM
Benzinga’s Top Pre- Market Losers (CADC, TIBX, PARD, HGSI, SHPGY, ATVI)
Benzinga
-
Nov 16, 2009, 9:00AM
Poniard Pharmaceuticals Shares Slammed
Benzinga
-
Nov 16, 2009, 8:01AM
Poniard Pharmaceuticals Announces Pivotal Phase 3 of Picoplatin Did Not Meet Primary Endpoint
Benzinga
-
Nov 16, 2009, 7:09AM
Friday, November 13, 2009
Poniard Pharmaceuticals Inc (NASDAQ:PARD) Highest Implied Volatility
Benzinga
-
Nov 13, 2009, 10:45AM